Ausgabe 5/2013
Inhalt (37 Artikel)
Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI
Kyung Won Kim, Jeong Min Lee, Yong Sik Jeon, In Joon Lee, YoonSeok Choi, Jisuk Park, Berthold Kiefer, Chin Kim, Joon Koo Han, Byung Ihn Choi
Role of IL-8 induced angiogenesis in uveal melanoma
Laura Lattanzio, Federica Tonissi, Ilaria Torta, Luca Gianello, Elvio Russi, Gerard Milano, Marco Merlano, Cristiana Lo Nigro
Digalloylresveratrol, a novel resveratrol analog inhibits the growth of human pancreatic cancer cells
Philipp Saiko, Geraldine Graser, Benedikt Giessrigl, Marie-Thérèse Steinmann, Heike Schuster, Andreas Lackner, Michael Grusch, Georg Krupitza, Walter Jaeger, Venkateswarlu Somepalli, Trimurtulu Golakoti, Monika Fritzer-Szekeres, Thomas Szekeres
Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA
Serena Marchetti, Dick Pluim, Monique van Eijndhoven, Olaf van Tellingen, Roberto Mazzanti, Jos H. Beijnen, Jan H. M. Schellens
Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas
Tina Dasgupta, Daphne A. Haas-Kogan, Xiaodong Yang, Aleksandra Olow, Daniel X. Yang, Ashley Gragg, Lisa A. Orloff, Sue S. Yom
Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer
Ruud P. M. Dings, Joseph I. Levine, Susan G. Brown, Lucile Astorgues-Xerri, John R. MacDonald, Thomas R. Hoye, Eric Raymond, Kevin H. Mayo
Novel bourgeonal fragrance conjugates for the detection of prostate cancer
Alexander Sturzu, Sumbla Sheikh, Hartmut Echner, Thomas Nägele, Martin Deeg, Christian Schwentner, Marius Horger, Ulrike Ernemann, Stefan Heckl
Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line
Yohei Funakoshi, Toru Mukohara, Hideo Tomioka, Roudy Chiminch Ekyalongo, Yu Kataoka, Yumiko Inui, Yuriko Kawamori, Masanori Toyoda, Naomi Kiyota, Yutaka Fujiwara, Hironobu Minami
Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner
Panagiotis J. Vlachostergios, Eleana Hatzidaki, Christina D. Befani, Panagiotis Liakos, Christos N. Papandreou
A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors
Ivan Diaz-Padilla, Hal Hirte, Amit M. Oza, Blaise A. Clarke, Brenda Cohen, Michael Reedjik, Tong Zhang, Suzanne Kamel-Reid, S. Percy Ivy, Sebastien J. Hotte, Albiruni A. R. Razak, Eric X. Chen, Irene Brana, Monika Wizemann, Lisa Wang, Lillian L. Siu, Philippe L. Bedard
Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies
Gerald S. Falchook, Siqing Fu, Aung Naing, David S. Hong, Wei Hu, Stacy Moulder, Jennifer J. Wheler, Anil K. Sood, Ernesto Bustinza-Linares, Kristin L. Parkhurst, Razelle Kurzrock
Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies
Shaji K. Kumar, James Jett, Randolph Marks, Ronald Richardson, Fernando Quevedo, Timothy Moynihan, Gary Croghan, Svetomir N. Markovic, Keith C. Bible, Rui Qin, Angelina Tan, Julian Molina, Scott H. Kaufmann, Charles Erlichman, Alex A. Adjei
Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck
Jean-Pascal Machiels, Marie-Christine Kaminsky, Ulrich Keller, Tim H. Brümmendorf, Thomas Goddemeier, Ulf Forssmann, Jean-Pierre Delord
Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome
Ivana Gojo, Alexander Perl, Selina Luger, Maria R. Baer, Kelly J. Norsworthy, Kenneth S. Bauer, Michael Tidwell, Stephanie Fleckinger, Martin Carroll, Edward A. Sausville
An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer
Joanne Brady, Pippa Corrie, Ian Chau, Raghunadharao Digumarti, Laurel M. Adams, Jeffrey Botbyl, Kevin H. Laubscher, Rachel S. Midgley, Mohandas Mallath
Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors
Cristiana Sessa, Gianluca Del Conte, Alexandre Christinat, Sara Cresta, Antonella Perotti, Elisa Gallerani, Pilar Lardelli, Carmen Kahatt, Vicente Alfaro, Jorge L. Iglesias, Carlos Fernández-Teruel, Luca Gianni
A Phase I Study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer
Balazs Halmos, Yuxia Jia, Joseph A. Bokar, Pingfu Fu, David J. Adelstein, Rosalyn Juergens, Mary Beth Rodal, Afshin Dowlati
Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies
Erin Schenk, Andrea E. Wahner Hendrickson, Donald Northfelt, David O. Toft, Matthew M. Ames, Michael Menefee, Daniel Satele, Rui Qin, Charles Erlichman
A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer
I. Garrido-Laguna, K. A. McGregor, M. Wade, J. Weis, W. Gilcrease, L. Burr, R. Soldi, L. Jakubowski, C. Davidson, G. Morrell, J. D. Olpin, K. Boucher, D. Jones, S. Sharma
Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor
Tetsuhide Ito, Takuji Okusaka, Toshirou Nishida, Kenji Yamao, Hisato Igarashi, Chigusa Morizane, Shunsuke Kondo, Nobumasa Mizuno, Kazuo Hara, Akira Sawaki, Satoshi Hashigaki, Nobuyuki Kimura, Mami Murakami, Emiko Ohki, Richard C. Chao, Masayuki Imamura
Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer
Isamu Okamoto, Keisuke Aoe, Terufumi Kato, Yukio Hosomi, Akira Yokoyama, Fumio Imamura, Katsuyuki Kiura, Tomonori Hirashima, Makoto Nishio, Naoyuki Nogami, Hiroaki Okamoto, Hideo Saka, Nobuyuki Yamamoto, Naoto Yoshizuka, Risa Sekiguchi, Kazuhiro Kiyosawa, Kazuhiko Nakagawa, Tomohide Tamura
Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study
Tim Eisen, Yaroslav Shparyk, Nicholas Macleod, Robert Jones, Gudrun Wallenstein, Graham Temple, Yasser Khder, Claudia Dallinger, Matus Studeny, Arsene-Bienvenu Loembe, Igor Bondarenko
A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2
Yousuke Nakai, Hiroyuki Isayama, Hideaki Ijichi, Takashi Sasaki, Naminatsu Takahara, Yukiko Ito, Saburo Matsubara, Rie Uchino, Hiroshi Yagioka, Toshihiko Arizumi, Tsuyoshi Hamada, Koji Miyabayashi, Suguru Mizuno, Keisuke Yamamoto, Hirofumi Kogure, Natsuyo Yamamoto, Kenji Hirano, Naoki Sasahira, Keisuke Tateishi, Minoru Tada, Kazuhiko Koike
A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer
K. H. Park, J. H. Sohn, S. Lee, J. H. Park, S. Y. Kang, H. Y. Kim, I. H. Park, Y. H. Park, Y. H. Im, H. J. Lee, D. S. Hong, S. Park, S. H. Shin, H. C. Kwon, J. H. Seo
A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109
Lida A. Mina, Menggang Yu, Cynthia Johnson, Cyndi Burkhardt, Kathy D. Miller, Robin Zon
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance)
Pankaj Gupta, Flora Mulkey, Robert P. Hasserjian, Ben L. Sanford, Ravi Vij, David D. Hurd, Olatoyosi M. Odenike, Clara D. Bloomfield, Kouros Owzar, Richard M. Stone, Richard A. Larson
Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer—CRAFT study
Tohru Tezuka, Chikuma Hamada, Hideyuki Ishida, Mitsuru Ooshiro, Hiroshi Matsuoka, Shingo Kawasaki, Hideyuki Mishima, Kotaro Maeda, Junichi Sakamoto, Keiji Koda
Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: Results of a Phase II trial
Craig Reynolds, Alexander I. Spira, Larry Gluck, Suzanne E. Mueller, Feng Zhan, Kristi A. Boehm, Lina Asmar
Patupilone in patients with pretreated metastatic/locally recurrent colorectal cancer: results of the Phase II CINATRA trial
S. Y. Moorcraft, I. Chau, C. Peckitt, D. Cunningham, S. Rao, K. L. Yim, A. Walther, C. G. C. A. Jackson, G. Stamp, J. Webb, G. Smith, A. Gillbanks, C. Swanton
Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study
David M. Hyams, Arlene Chan, Celia de Oliveira, Raymond Snyder, Jeferson Vinholes, M. William Audeh, Victor M. Alencar, Janine Lombard, Bijoyesh Mookerjee, John Xu, Kathryn Brown, Paula Klein
In silico analysis of the amido phosphoribosyltransferase inhibition by PY873, PY899 and a derivative of isophthalic acid
Sidra Batool, Muhammad Sulaman Nawaz, Mohammad A. Kamal
Bronchoscopic findings for bevacizumab-related pulmonary hemorrhage in advanced non–small cell lung cancer
Kunio Okamoto, Isamu Okamoto, Masaki Miyazaki, Kaoru Tanaka, Hiroyasu Kaneda, Kazuhiko Nakagawa
Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors
Changhoon Yoo, Min-Hee Ryu, Baek-Yeol Ryoo, Mo Youl Beck, Yoon-Koo Kang
The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer
Mohamed A. Khalil, Wei Qiao, Peter Carlson, Binsah George, Milind Javle, Michael Overman, Gauri Varadhachary, Robert A. Wolff, James L. Abbruzzese, David R. Fogelman
Erratum to: Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer
Isamu Okamoto, Keisuke Aoe, Terufumi Kato, Yukio Hosomi, Akira Yokoyama, Fumio Imamura, Katsuyuki Kiura, Tomonori Hirashima, Makoto Nishio, Naoyuki Nogami, Hiroaki Okamoto, Hideo Saka, Nobuyuki Yamamoto, Naoto Yoshizuka, Risa Sekiguchi, Kazuhiro Kiyosawa, Kazuhiko Nakagawa, Tomohide Tamura
Erratum to: Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI
Kyung Won Kim, Jeong Min Lee, Yong Sik Jeon, In Joon Lee, YoonSeok Choi, Jisuk Park, Berthold Kiefer, Chin Kim, Joon Koo Han, Byung Ihn Choi